Publications by Gianni Sava | EPFL Graph Search

Lysozyme-Induced Transcriptional Regulation of TNF-alpha Pathway Genes in Cells of the Monocyte Lineage

Paul Joseph Dyson, Florence Armand, Romain Hamelin, Gianni Sava, Isabelle Mireille Claude Schepens

Lysozyme is one of the most important anti-bacterial effectors in the innate immune system of animals. Besides its direct antibacterial enzymatic activity, lysozyme displays other biological properties, pointing toward a significant anti-inflammatory effec ...

2019

The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions

Paul Joseph Dyson, Gianni Sava

Platinum drugs are extensively used in the clinic to treat cancer, often leading to a palliative response rather than a cure. While DNA is considered to be the primary target of platinum drugs, there is no clear relationship between cellular platinum accum ...

2018

The Differential Distribution of RAPTA-T in Non-Invasive and Invasive Breast Cancer Cells Correlates with Its Anti-Invasive and Anti-Metastatic Effects

Paul Joseph Dyson, Graham Knott, Anders Meibom, Stéphane Laurent Escrig, Gianni Sava, Catherine Maclachlan

Nanoscale secondary ion mass spectrometry (NanoSIMS) combined with transmission electron microscopy (TEM) can be a powerful approach to visualize the exact distribution of drugs at the sub-cellular level. In this work, we exploit this approach to identify ...

2017

Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer

Paul Joseph Dyson, Tina Riedel, Gianni Sava

Aim of the study The tumor metastases targeting ruthenium complex NAMI-A synergistically improves the activity of gemcitabine in combination therapies. High-throughput screening was used to identify other potential drug combinations from a library of FDA a ...

Springer2015

Metal-based antitumour drugs in the post-genomic era: what comes next?

Paul Joseph Dyson, Gianni Sava

In our Dalton Transactions Perspective article entitled, 'Metal-based antitumour drugs in the post genomic era', (Dalton Trans., 2006, 1929-1933) we discussed metal-based drugs in light of past decades of research. We concluded that the post-genomic era wo ...

2011

Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound

Paul Joseph Dyson, Gianni Sava

The modulation of the metastatic progression of breast cancer has been evaluated in vitro and in vivo with RAPTA-T, [Ru(η6-toluene)Cl2(PTA)], an organometallic ruthenium compd. In vitro RAPTA-T inhibits some steps of the metastatic process such as the deta ...

2008

Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy

Paul Joseph Dyson, Claudine Scolaro, Christian Hartinger, Gianni Sava

The antitumor activity of the organometallic ruthenium(II)-arene mixed phosphine complexes, [Ru(h6-p-cymene)Cl(PTA)(PPh3)]BF4 1b and [Ru(h6-C6H5CH2CH2OH)Cl(PTA)(PPh3)]BF4 2b (PTA = 1,3,5-triaza-7-phosphaadamantane), have been evaluated in vitro and compare ...

2007

Development of Ruthenium Antitumor Drugs that Overcome Multidrug Resistance Mechanisms

Rosario Scopelliti, Paul Joseph Dyson, Claudine Scolaro, Wee Han Ang, Andrew Douglas Phillips, Gianni Sava

Organometallic ruthenium(II) complexes of the general formula [Ru(η6-p-cymene)Cl2(L)] and [Ru(η6-p-cymene)Cl(L)2][BPh4] with modified phenoxazine- and anthracene-based multidrug resistanc ...

2007

The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy

Paul Joseph Dyson, Gianni Sava

The aim of the study is to evaluate the differences of protein binding of NAMI-A, a new ruthenium drug endowed with selective antimetastatic properties, and of cisplatin and to ascertain the possibility to use two drugs based on heavy metals in combination ...

2006

Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds

Sébastien Rochat, Paul Joseph Dyson, Ursula Röthlisberger, Ivano Tavernelli, Antoine Dorcier, Christian Gossens, Claudine Scolaro, Gianni Sava

A new series of organometallic ruthenium(II)-arene compounds of the type RuCl2(η6-arene)(phosphine) (phosphine = 1,3,5-triaza-7-phosphaadamantane, PTA, and 3,7-diacetly-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane, DAPTA) with different ...

2006

Synthesis, Characterization, and in Vitro Evaluation of Novel Ruthenium(II) η6-Arene Imidazole Complexes

Rosario Scopelliti, Paul Joseph Dyson, Claudine Scolaro, Andrew Douglas Phillips, Gianni Sava

Ten complexes of general formula [Ru(η6-arene)Cl2(L)], [Ru(η6-arene)Cl(L)2][X], and [Ru(η6-arene)(L)3][X]2 (η6-arene = benzene, p-cymene; L = imidazole, ...

2006

Metal-based antitumour drugs in the post genomic era

Paul Joseph Dyson, Gianni Sava

The discovery of new metal-based antitumor drugs, whether cisplatin derivs. or those based on other metals, has been largely based on cell viability assays (IC50 values) and compds. that bind to DNA. This approach has been applied for more than 30 years du ...

2006

In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes

Gabor Laurenczy, Paul Joseph Dyson, Claudine Scolaro, Gianni Sava

The antitumor activity of the organometallic ruthenium(II)-arene complexes, RuCl2(eta(6)-arene)(PTA), (arene = p-cymene, toluene, benzene, benzo-15-crown-5, 1-ethylbenzene-2,3-dimethylimidazolium tetrafluoroborate, ethyl benzoate, hexamethylbenzene; PTA = ...

2005